MALDI TOF News and Research

RSS

Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry is a soft ionization method used in the detection of various chemical compounds with a broad mass range. MALDI-TOF can be applied in biology to the study of nucleic acids and proteins.

RapifleX MALDI PharmaPlus Solution for uHTS launched by Bruker

At the 64th ASMS Conference, Bruker announces the launch of the new rapifleX™ MALDI PharmaPulse™ (MPP) solution. It is the latest addition to Bruker’s portfolio of innovative products designed to assist pharmaceutical, biotech and CRO customers to accelerate drug discovery, and rapifleX MPP can dramatically lower the cost of ultra-high throughput screening (uHTS) with further improved results.

From Bruker Daltonics 7 Jun 2016

Innovative RapifleX MALDI-TOF/TOF showcased by Bruker

At the 64th ASMS Conference, Bruker introducesrapifleX™, the highest performance MALDI-TOF/TOF mass spectrometer, which had been shown as work-in-progress to early adopters at HUPO 2015.

From Bruker Daltonics 7 Jun 2016

Bruker showcases new products, analytical solutions for improved performance at Analytica 2016

This week at Analytica 2016, Bruker is showcasing new products and analytical solutions for improved performance and customer experience in pharmaceutical, industrial and applied markets.

From Bruker BioSpin Group 11 May 2016

Bruker receives CFDA clearance to market IVD MALDI Biotyper System in China

Bruker Corporation today announced that it has received clearance from the China Food and Drug Administration to market and sell its IVD MALDI Biotyper System as a medical device in China for the identification of microorganisms isolated from human specimens.

From Bruker 25 Jun 2014

Agena Bioscience expands ultrasensitive somatic mutation detection technology

Agena Bioscience, Inc., which recently acquired the Bioscience business of Sequenom, Inc., today announced expansion of the UltraSEEK™ technology, the first ultrasensitive somatic mutation detection technology for high-throughput and definitive interrogation of rare mutations that occur at less than 1% abundance in matched tissue, circulating plasma, and tumor samples.

31 May 2014

Agena Bioscience acquires Sequenom’s Bioscience business

Agena Bioscience, Inc., a portfolio company of Telegraph Hill Partners (THP), today acquired the Bioscience business of Sequenom, Inc., which sells the MassARRAY® System for mass spectrometry-based detection of nucleic acids in research and clinical laboratories.

31 May 2014

New method for identifying bacteria in patient specimens leads to 92% cost reduction

Researchers at UNC Health Care have found that using a new method for identifying bacteria and fungi in patient specimens led to a 92 percent cost reduction in the reagents needed to run clinical microbiology tests.

21 May 2014

Bruker launches new, improved customer-driven products at Pittcon 2014

At Pittcon 2014, Bruker today announced new product introductions and enhancements for improved performance and customer experience in research, industrial and applied markets.

4 Mar 2014

Bruker receives FDA clearance to market MALDI Biotyper CA System in the U.S.

Bruker Corporation today announced that it has been granted U.S. FDA clearance under Section 510(k) to market its MALDI Biotyper CA System in the United States for the identification of Gram negative bacterial colonies cultured from human specimens.

26 Nov 2013

Early detection of breast cancer could soon be possible with blood test

What could someday be the first blood test for the early detection of breast cancer was shown in preliminary studies to successfully identify the presence of breast cancer cells from serum biomarkers, say the Houston Methodist Research Institute scientists who are developing the technology.

15 Nov 2013

Sequenom announces Certified Service Provider program for technical certification

Sequenom, Inc., a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced a Certified Service Provider (CSP) program for the technical certification of selected laboratories offering research services using the Sequenom research-use-only MassARRAY System.

18 Sep 2013

Bruker Launches Second Phase Of SISCAPA-MALDI Collaboration

After focusing on confirming the utility and quantitative precision of the SISCAPA-MALDI workflow in the collaboration's first phase, Bruker said it plans to establish fully automated SISCAPA-MALDI capabilities in its demonstration facilities.

16 Sep 2013

FDA approves first mass spectrometer system in U.S. for identification of bacteria, yeasts

The U.S. Food and Drug Administration today allowed marketing in the U.S. of the first mass spectrometer system for automated identification of bacteria and yeasts that are known to cause serious illness in humans.

22 Aug 2013

Bruker launches BioPharmaCompass 1.1 software

At the 2012 CASSS 9th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry, Bruker today launches the first software solution to encompass the complete biopharmaceutical characterization challenge, including glycoforms, impurities and modifications.

From Bruker BioSpin Group 12 Sep 2012

Accelr8 expands development plan for BACcel rapid diagnostic test

Accelr8 Technology Corporation announced that it successfully completed two technical feasibility studies for test methods that expand its BACcel rapid diagnostic test library and automation capabilities.

23 Nov 2011

Bruker to showcase record performance achievements of maXis 4G system at ASMS 2011

Bruker, the pioneer of ultrahigh-resolution quadrupole time-of-flight mass spectrometry, today announced a major extension of the successful maXis UHR Qq-TOF technology range, which Bruker will showcase at the ASMS 2011 conference in Denver, Colorado, starting this Sunday, June 5.

3 Jun 2011

NewGene develops breakthrough test for hereditary breast cancer

A new breakthrough test for hereditary breast cancer developed by UK-based NewGene could see thousands of women being diagnosed with the genetic condition in around half the usual time and at around half the cost of conventional test methods.

16 May 2011

New technique can reveal fat distribution in healthy human brain

Mapping the fat distribution of the healthy human brain is a key step in understanding neurological diseases, in general, and the neurodegeneration that accompanies Alzheimer's disease in particular. Antonio Veloso and colleagues, from the University of the Basque Country in Leioa, Spain, find a new technique to reveal the fat distribution of three different areas of the healthy human brain.

5 May 2011

Bruker receives Health Canada approval for IVD MALDI Biotyper

At the 2011 Annual Meeting of the Canadian Association for Clinical Microbiology and Infectious Diseases, the companies i2A Canada and Bruker Ltd. announced together that they have met the relevant Health Products and Food Branch of Health Canada regulations for the Bruker IVD MALDI Biotyper, and that this product is now available for sale as a Class 1 Medical Device to all clinical microbiology sites in Canada.

8 Apr 2011

ICR, AB SCIEX collaborate to standardize mass spectrometry-based tissue imaging

A key research area for The Institute of Cancer Research is investigating the spread of cancer in the human body in an effort to identify new and effective treatment strategies. To help advance this research, the ICR is collaborating with scientists at AB SCIEX, a global leader in life science analytical technologies, to standardize advanced methods of mass spectrometry-based tissue imaging.

17 Feb 2011